NCT06475404View on ClinicalTrials.gov

A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 6, 2023

Primary Completion Date

September 20, 2023

Study Completion Date

September 20, 2023

Conditions
Mucopolysaccharidosis Type IIMetabolic Diseases
Interventions
BIOLOGICAL

verenafusp alfa 6 mg/kg

Single intravenous administration of 6 mg/kg of verenafusp alfa

BIOLOGICAL

verenafusp alfa 9 mg/kg

Single intravenous administration of 9 mg/kg of verenafusp alfa

BIOLOGICAL

verenafusp alfa 12 mg/kg

Single intravenous administration of 12 mg/kg of verenafusp alfa

Trial Locations (1)

117556

"State budgetary healthcare institution of the city of Moscow City Clinic No. 2 of the Moscow Health Department", Moscow

All Listed Sponsors
lead

AO GENERIUM

INDUSTRY